Biogen criticized in the US over price of new Alzheimer's drug

Bloomberg News reports that treating 1 million patients will cost around USD 57bn annually according to an estimate made by the Kaiser Family Foundation.
Photo: Steven Senne/AP/Ritzau Scanpix
Photo: Steven Senne/AP/Ritzau Scanpix
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The price tag of Biogen's new Alzheimer's medication Aduhelm has raised criticism and concern in the US. Soon, authorities will decide the extent of the available support schemes and the patient groups that will be offered the medication, according to Bloomberg News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading